4CPS-146 Ustekinumab and adalimumab for psoriasis patients who are no-responders to etanercept: a comparative effectiveness study

BACKGROUND: Adalimumab and ustekinumab have demonstrated high effectiveness in the treatment of moderate-severe psoriasis in randomised controlled trials. There is, however, limited data available on the comparative effectiveness of ustekinumab and adalimumab in psoriasis patients unsuccessfully tre...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Eur J Hosp Pharm
Main Authors: Gil, S García, Nicolás, F Gutiérrez, Casariego, GJ Nazco, Bustinduy, M García, Martín-Neda, FJ Guimerá, Ramos, J Rodríguez, García, B del Rosario, García, J González
Format: Artigo
Jezik:Inglês
Izdano: BMJ Group 2018
Teme:
Section 4: Clinical pharmacy services
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535744/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.237
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki